Oculis reports Q3 2026 results, discloses Accure asset purchase and expanded ATM program
The Swiss biopharma agreed to acquire Accure Therapeutics' rights to lead candidate Privosegtor and expanded its at-the-market share sale facility to $125 million.
Oculis Holding AG reported unaudited financial results for the three and nine months ended September 30, 2026, filed with the SEC on November 3, 2026.
On August 10, 2026, Oculis entered into an asset purchase agreement with Accure Therapeutics, S.L. to acquire all of Accure's worldwide development and commercial rights to Privosegtor.1 Under the agreement, upon closing Oculis will acquire Accure's rights to Privosegtor (ACT-01) and ACT-02, an early-stage preclinical neurology drug candidate, subject to the satisfaction of applicable closing conditions.1 Total consideration includes an up-front payment of $3.8 million (CHF 3.2 million) in cash and up to 2,050,000 Oculis ordinary shares, split between up-front shares subject to a lockup release over up to 2 years and earnout shares tied to development and regulatory milestones.1 The transaction had not yet closed as of the date of the financial statements, and the company had not finalized its assessment of the deal's impact.1
On pipeline progress, the company noted that the OCS-01 DIAMOND-1 and DIAMOND-2 trials in diabetic macular edema were completed during the second quarter of 2026.1
On financing, on November 3, 2026 Oculis signed Amendment No. 1 to its Amended and Restated Sales Agreement with Leerink Partners, LLC, under which the company may offer and sell ordinary shares having an aggregate offering price of up to $125 million through its ATM Program.1 As of the date of the financial statements, no shares had been sold under the new prospectus supplement.1
On cash position, Oculis held CHF 66,292 thousand in cash and cash equivalents and CHF 143,999 thousand in short-term financial assets as of September 30, 2026.1 The Board of Directors said that based on current cash, cash equivalents and investments, the company has the ability to meet its financial obligations for at least the next 12 months.1 The company described itself as late clinical-stage, exposed to substantial uncertainty over whether current projects will succeed.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.